SYNGENE - Trademark Details
Status: 700 - Registered
Serial Number
88981754
Registration Number
6405032
Word Mark
SYNGENE
Status
700 - Registered
Status Date
2021-06-29
Filing Date
2018-08-16
Registration Number
6405032
Registration Date
2021-06-29
Mark Drawing
5000 - Illustration: Drawing with word(s)/letter(s)/number(s) in Stylized form
Typeset
Published for Opposition Date
2020-01-14
Attorney Name
Law Office Assigned Location Code
M70
Employee Name
BRACEY, KAREN E
Statements
Indication of Colors claimed
Color is not claimed as a feature of the mark.
Description of Mark
The mark consists of the word "Syngene" in stylized font.
Goods and Services
Business services, namely, formulation of best practices for drug discovery, formulation development, clinical supplies, large molecule development, antibody drug conjugates and clinical development services; consulting services in the field of medical practice management for others; business consulting and management in the field of clinical trials, namely, providing information management services; business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; regulatory submission management, namely, assisting others in preparing and filing applications for new drugs with governmental regulatory bodies; business management consulting services in the field of pharmaceuticals drug development; none of the aforesaid services relating to gel imaging and gel analysis applications
Goods and Services
Scientific research and custom synthesis; scientific and clinical research in the field of medicine, pharmaceutical, nutraceuticals; scientific research and development; custom design and development of chemical reagents and biochemical assays; laboratory testing; laboratory testing services for research and development purposes; testing of pharmaceuticals; chemical engineering; drug discovery services; pharmaceutical drug development services; pharmaceutical products development; development of pharmaceutical preparations and medicines; scientific study and research in the field of reproduction, husbandry, and general health of animal; biotechnology research for determining the neuronal survival of molecules in animal models; research and development services in the field of antibodies, antibody technology; custom design and development of chemical reagents and biochemical assays; design, engineering, research, development and testing services in the field of polymeric materials, polymer synthesis, and materials customization for medical, scientific, and technological applications; toxicology services; toxicity analysis; toxicity testing for research purposes; conducting clinical trials; conducting clinical trials for scientific research for others; conducting clinical trials for pharmaceutical products; providing medical and scientific research information in the field of clinical trials; conducting early evaluations in the field of new pharmaceuticals; DNA analysis services for scientific research purposes; laboratory research in the field of gene expression; blood analysis services for scientific research purposes; analysis of human tissues for medical research; scientific services relating to the isolation and cultivation of human tissues and cells for research purposes; preparation of reports relating to scientific and technical research; analysis in the field of molecular biology; contract research services relating to molecular sciences; biological cloning services; structural and functional analysis of genomes; scientific and medical laboratory services; services of a chemical and/or biological laboratory; laboratory research services relating to pharmaceuticals; research and development and consultation related thereto in the field of antibodies, antibody technology, chemistry, bioinformatics, biomedical devices, biologics, biotechnology, biotherapeutics, biology, biochemical preparations, cell lines, cheminformatics, genetics and genetic engineering, gene expression systems, in vitro research, inhalation pharmaceuticals, molecular sciences, micro-organisms, nutrition, ophthalmic preparations, pharmacogenetics, pharmacokinetics, pharmacology, pharmaceuticals, polymers, peptide synthesis, protein, and solid state characterization; toxicokinetic analysis and toxicology services; scientific and technological services, namely, scientific research, development, analysis, testing, engineering, extraction, synthesis, purification and production in the field of antibodies, active pharmaceutical ingredients (API), biomolecules, cell bank characterization, chirality, chromosome aberration, clinical chemistry, cloning vector, cyclotides, DNA, flow cytometry, gas chromatography mass spectrometry, genes, immuno-pharmaceuticals, in vitro irritation, large molecule, liquid chromatography mass spectrometry, microbials, monomers, nanoparticles, natural products, peptides, proteins, RNA, supercritical fluid chromatography, small molecules and vaccines; none of the aforesaid services relating to gel imaging and gel analysis applications, and none of the aforesaid services in the field of agriculture, horticulture and forestry
Classification Information
International Class
035 - Advertising; business management; business administration; office functions. - Advertising; business management; business administration; office functions.
US Class Codes
100, 101, 102
Class Status Code
6 - Active
Class Status Date
2018-08-25
Primary Code
035
First Use Anywhere Date
2004-08-31
First Use In Commerce Date
2004-08-31
International Class
042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services. - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services.
US Class Codes
100, 101
Class Status Code
6 - Active
Class Status Date
2018-08-25
Primary Code
042
First Use Anywhere Date
2004-08-31
First Use In Commerce Date
2004-08-31
Current Trademark Owners
Party Name
Party Type
30 - Original Registrant
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Name
Party Type
30 - Original Registrant
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
20 - Owner at Publication
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
10 - Original Applicant
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Lawrence E. Abelman
Address
Please log in with your Justia account to see this address.
Prior Registrations
Relationship Type | Reel Number |
Continuity Parent | 88081490 |
Trademark Events
Event Date | Event Description |
2018-08-20 | NEW APPLICATION ENTERED IN TRAM |
2018-08-25 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2018-12-03 | ASSIGNED TO EXAMINER |
2018-12-06 | NON-FINAL ACTION WRITTEN |
2018-12-06 | NON-FINAL ACTION E-MAILED |
2018-12-06 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2019-06-04 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2019-06-04 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2019-06-04 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2019-06-04 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
2019-06-11 | NON-FINAL ACTION WRITTEN |
2019-06-11 | NON-FINAL ACTION E-MAILED |
2019-06-11 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2019-12-11 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2019-12-11 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2019-12-11 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2019-12-12 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2019-12-25 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
2020-01-14 | PUBLISHED FOR OPPOSITION |
2020-01-14 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
2020-02-11 | EXTENSION OF TIME TO OPPOSE RECEIVED |
2020-06-02 | TEAS POST PUBLICATION AMENDMENT RECEIVED |
2020-06-24 | ASSIGNED TO PETITION STAFF |
2020-06-26 | CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED |
2020-07-23 | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED |
2020-09-01 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
2021-03-01 | TEAS EXTENSION RECEIVED |
2021-03-01 | EXTENSION 1 FILED |
2021-03-01 | EXTENSION 1 GRANTED |
2021-03-03 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2021-05-06 | TEAS STATEMENT OF USE RECEIVED |
2021-05-06 | TEAS REQUEST TO DIVIDE RECEIVED |
2021-05-26 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
2021-05-06 | DIVISIONAL REQUEST RECEIVED |
2021-05-26 | DIVISIONAL PROCESSING COMPLETE |
2021-05-06 | USE AMENDMENT FILED |
2021-05-26 | STATEMENT OF USE PROCESSING COMPLETE |
2021-05-27 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
2021-05-28 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
2021-06-29 | REGISTERED-PRINCIPAL REGISTER |